Therapeutic Response

ER positive and HER2-negative status confers therapeutic sensitivity to Abemaciclib in combination with Fulvestrant in patients with Invasive Breast Carcinoma.

Statements

Source and description
Verzenio (abemaciclib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
Faslodex (fulvestrant) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.